Mylan scores multiple sclerosis patent win over Biogen

Mylan has succeeded in having a key Biogen patent covering multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) invalidated by a US federal court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Biogen loses another battle over MS drug patent

21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

More on this story

Biotechnology

Biogen loses another battle over MS drug patent

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

More on this story

Biotechnology

Biogen loses another battle over MS drug patent

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.